Free Trial
NASDAQ:BYSI

BeyondSpring Q1 2025 Earnings Report

BeyondSpring logo
$1.92 +0.20 (+11.63%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$1.88 -0.04 (-2.34%)
As of 09/19/2025 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BeyondSpring EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BeyondSpring Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BeyondSpring Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Monday, May 12, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

BeyondSpring's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

BeyondSpring Earnings Headlines

2013 Bitcoin miner reveals his trading system (free)
While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematically extracting profits from the $4 billion that changes hands in crypto every single day.tc pixel
See More BeyondSpring Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeyondSpring? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeyondSpring and other key companies, straight to your email.

About BeyondSpring

BeyondSpring (NASDAQ:BYSI) Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity. Plinabulin is being evaluated in multiple clinical trials for the prevention of chemotherapy-induced neutropenia and as a potential combination therapy in metastatic non-small cell lung cancer. BeyondSpring has secured Fast Track designation from the U.S. Food and Drug Administration for plinabulin’s use in neutropenia prevention, underscoring the agent’s differentiated mechanism of action and its potential to reduce chemotherapy-related complications.

BeyondSpring’s broader pipeline includes bezuclastinib, a selective tyrosine kinase inhibitor being studied for the treatment of advanced systemic mastocytosis and related disorders. This program highlights the company’s strategy of in-licensing or acquiring assets with first-in-class or best-in-class potential. BeyondSpring maintains research collaborations and conducts pharmacology and safety evaluations through its integrated facilities in Suzhou, as well as through partnerships with academic institutions and contract research organizations in North America and Europe.

Founded in 2010, BeyondSpring completed its initial public offering on the NASDAQ in 2019 under the ticker symbol BYSI. The company is led by President and Chief Executive Officer Mitchell Gold, alongside co-founder and Executive Chairman Dr. John Li, supported by a management team with extensive expertise in oncology drug development, regulatory affairs and global commercialization. BeyondSpring continues to advance its pipeline through late-stage clinical programs and regulatory filings, with the goal of bringing novel cancer therapeutics to patients worldwide.

View BeyondSpring Profile

More Earnings Resources from MarketBeat